BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25529107)

  • 1. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality.
    Ay C; Posch F; Kaider A; Zielinski C; Pabinger I
    J Thromb Haemost; 2015 Mar; 13(3):390-7. PubMed ID: 25529107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort.
    Blix K; Gran OV; Severinsen MT; Cannegieter SC; Jensvoll H; Overvad K; Hammerstrøm J; Tjønneland A; Naess IA; Braekkan SK; Rosendaal FR; Kristensen SR; Hansen JB
    J Thromb Haemost; 2018 Jul; 16(7):1327-1335. PubMed ID: 29691978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study.
    Stender MT; Larsen TB; Sørensen HT; Thorlacius-Ussing O
    J Thromb Haemost; 2012 Oct; 10(10):2027-31. PubMed ID: 22900573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
    Moik F; Prager G; Thaler J; Posch F; Wiedemann S; Schramm T; Englisch C; Mackman N; Pabinger I; Ay C
    Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2837-2847. PubMed ID: 34470475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.
    Riedl J; Kaider A; Marosi C; Prager GW; Eichelberger B; Assinger A; Pabinger I; Panzer S; Ay C
    Thromb Haemost; 2017 Jan; 117(1):90-98. PubMed ID: 27761580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients.
    Mauracher LM; Posch F; Martinod K; Grilz E; Däullary T; Hell L; Brostjan C; Zielinski C; Ay C; Wagner DD; Pabinger I; Thaler J
    J Thromb Haemost; 2018 Mar; 16(3):508-518. PubMed ID: 29325226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.
    Königsbrügge O; Posch F; Riedl J; Reitter EM; Zielinski C; Pabinger I; Ay C
    Oncologist; 2016 Feb; 21(2):252-7. PubMed ID: 26764252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
    Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
    J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients - results from the Vienna Cancer And Thrombosis Study (CATS).
    Pabinger I; Ay C; Dunkler D; Thaler J; Reitter EM; Marosi C; Zielinski C; Mannhalter C
    J Thromb Haemost; 2015 Jan; 13(1):17-22. PubMed ID: 25381723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
    Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
    J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombosis risk and survival in cancer patients with elevated C-reactive protein.
    Kanz R; Vukovich T; Vormittag R; Dunkler D; Ay C; Thaler J; Haselböck J; Scheithauer W; Zielinski C; Pabinger I
    J Thromb Haemost; 2011 Jan; 9(1):57-63. PubMed ID: 20874781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.
    Reitter EM; Kaider A; Ay C; Quehenberger P; Marosi C; Zielinski C; Pabinger I
    J Thromb Haemost; 2016 Feb; 14(2):294-305. PubMed ID: 26662117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
    Cohen AT; Katholing A; Rietbrock S; Bamber L; Martinez C
    Thromb Haemost; 2017 Jan; 117(1):57-65. PubMed ID: 27709226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model.
    Eichinger S; Heinze G; Kyrle PA
    J Am Heart Assoc; 2014 Jan; 3(1):e000467. PubMed ID: 24385451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.
    Fuentes HE; Oramas DM; Paz LH; Wang Y; Andrade XA; Tafur AJ
    J Gastrointest Cancer; 2018 Dec; 49(4):415-421. PubMed ID: 28634671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.
    Mego M; Zuo Z; Gao H; Cohen EN; Giordano A; Tin S; Anfossi S; Jackson S; Woodward W; Ueno NT; Valero V; Alvarez RH; Hortobagyi GN; Khoury JD; Cristofanilli M; Reuben JM
    Thromb Haemost; 2015 Mar; 113(3):593-8. PubMed ID: 25373787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study.
    Galanaud JP; Sevestre MA; Pernod G; Genty C; Richelet S; Kahn SR; Boulon C; Terrisse H; Quéré I; Bosson JL
    J Thromb Haemost; 2017 May; 15(5):907-916. PubMed ID: 28266773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study.
    Cugno M; Marzano AV; Bucciarelli P; Balice Y; Cianchini G; Quaglino P; Calzavara Pinton P; Caproni M; Alaibac M; De Simone C; Patrizi A; Cozzani E; Papini M; Tedeschi A; Berti E; Rosendaal FR;
    Thromb Haemost; 2016 Jan; 115(1):193-9. PubMed ID: 26245987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism.
    Parpia S; Julian JA; Thabane L; Lee AY; Rickles FR; Levine MN
    Contemp Clin Trials; 2011 Nov; 32(6):829-33. PubMed ID: 21777700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.
    Mrozinska S; Cieslik J; Broniatowska E; Malinowski KP; Undas A
    J Thromb Haemost; 2019 Nov; 17(11):1912-1922. PubMed ID: 31323706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.